These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 18785316)

  • 1. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
    J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
    De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F
    Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Vis M; van der Horst AR; Wolbink GJ; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Lems WF; Nurmohamed MT; Aarden L; Hamann D
    Ann Rheum Dis; 2009 Apr; 68(4):558-63. PubMed ID: 18445623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.
    Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP
    Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis.
    Vis M; Bos WH; Wolbink G; Voskuyl AE; Twisk JW; Van de Stadt R; Hamann D; Dijkmans BA; Lems WF
    J Rheumatol; 2008 Mar; 35(3):425-8. PubMed ID: 18322974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
    Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
    J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives.
    Hitchon CA; Chandad F; Ferucci ED; Willemze A; Ioan-Facsinay A; van der Woude D; Markland J; Robinson D; Elias B; Newkirk M; Toes RM; Huizinga TW; El-Gabalawy HS
    J Rheumatol; 2010 Jun; 37(6):1105-12. PubMed ID: 20436074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
    Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
    Atzeni F; Sarzi-Puttini P; Dell' Acqua D; de Portu S; Cecchini G; Cruini C; Carrabba M; Meroni PL
    Arthritis Res Ther; 2006; 8(1):R3. PubMed ID: 16356192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis.
    Ahmed MM; Mubashir E; Wolf RE; Hayat S; Hall V; Shi R; Berney SM
    South Med J; 2006 Nov; 99(11):1209-15. PubMed ID: 17195414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
    Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
    Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
    Bruns A; Nicaise-Roland P; Hayem G; Palazzo E; Dieudé P; Grootenboer-Mignot S; Chollet-Martin S; Meyer O
    Joint Bone Spine; 2009 May; 76(3):248-53. PubMed ID: 19208451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
    Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
    Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes.
    Barra L; Bykerk V; Pope JE; Haraoui BP; Hitchon CA; Thorne JC; Keystone EC; Boire G;
    J Rheumatol; 2013 Aug; 40(8):1259-67. PubMed ID: 23378461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis.
    Cantaert T; van Baarsen LG; Wijbrandts CA; Thurlings RM; van de Sande MG; Bos C; van der Pouw Kraan TC; Verweij CL; Tak PP; Baeten DL
    Rheumatology (Oxford); 2010 Jan; 49(1):156-66. PubMed ID: 19933783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
    Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
    J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
    Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
    J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should anti-citrullinated protein antibody and rheumatoid factor status be reassessed during the first year of followup in recent-onset arthritis? A longitudinal study.
    Mjaavatten MD; van der Heijde DM; Uhlig T; Haugen AJ; Nygaard H; Bjørneboe O; Kvien TK
    J Rheumatol; 2011 Nov; 38(11):2336-41. PubMed ID: 21965645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.